Zolimomab aritox

From Self-sufficiency

Revision as of 13:56, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Zolimomab aritox
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	CD5
Identifiers
CAS Number	141483-72-9
ATC code	none

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus^[1] and graft-versus-host disease^[2], but the studies failed to show positive effects of the drug.

It is an anti-CD5 antibody which is linked to the A chain of the ricin protein (which is reflected by the aritox in the drug's name).^[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitor: Azathioprine · Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide · Teriflunomide antifolate: Methotrexate
Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus · Ciclosporin · Pimecrolimus Abetimus · Gusperimus
TNF-α inhibitor	Thalidomide · Lenalidomide

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra
mTOR	Sirolimus · Deforolimus · Everolimus · Temsirolimus · Zotarolimus · Biolimus A9

Extracellular

Serum target (noncellular)	Complement component 5 (Eculizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) · Interleukin 5 (Mepolizumab) · Immunoglobulin E (Omalizumab) · BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab, Ustekinumab)
Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 (Clenoliximab, Keliximab, Zanolimumab) · CD11a (Efalizumab) · CD18 (Erlizumab) · CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 (Lumiliximab) · CD40 (Teneliximab, Toralizumab) · CD62L/L-selectin (Aselizumab) · CD80 (Galiximab) · CD147/Basigin (Gavilimomab) · CD154 (Ruplizumab) BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)
Unsorted	Atorolimumab, Cedelizumab, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab

-cept (Fusion)

proc, drug(L3/4)

v t e Mouse monoclonal antibodies ("-o-")
"-govo-" (ovarian tumor)	Abagovomab, Igovomab, Oregovomab
"-limo-" (immune system)	Afelimomab, Elsilimomab, Faralimomab, Gavilimomab, Inolimomab, Maslimomab, Nerelimomab, Odulimomab, Telimomab aritox, Vepalimomab, Zolimomab aritox
"-tumo-" (miscellaneous tumor)	Altumomab pentetate, Anatumomab mafenatox, Arcitumomab, Bectumomab, Blinatumomab, CC49, Detumomab, Ibritumomab tiuxetan, Minretumomab, Mitumomab, Naptumomab estafenatox, Nofetumomab merpentan, Pemtumomab, Pintumomab, Satumomab pendetide, Taplitumomab paptox, Tenatumomab, Tositumomab, 3F8
"-leso-" (infectious lesions)	Besilesomab, Fanolesomab^§, Lemalesomab, Sulesomab
"-ciro-" (cardiovascular)	Biciromab^§, Imciromab^§
"-pro-" (prostate tumor)	Capromab pendetide
"-baco-" (bacterial)	Edobacomab
"-colo-" (colonic tumor)	Edrecolomab, Nacolomab tafenatox
^§Withdrawn

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

40px	This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. v d e

↑ Stafford, FJ; Fleisher, TA; Lee, G; Brown, M; Strand, V; Austin Ha, 3rd; Balow, JE; Klippel, JH (1994). "A pilot study of anti-CD5 ricin a chain immunoconjugate in systemic lupus erythematosus". The Journal of rheumatology. 21 (11): 2068–70. PMID 7532717.
↑ Przepiorka, D; Lemaistre, CF; Huh, YO; Luna, M; Saria, EA; Brown, CT; Champlin, RE (1994). "Evaluation of anti-CD5 ricin a chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation". Therapeutic immunology. 1 (2): 77–82. PMID 7584486.
↑ WHO Drug Information